Andere Sprachen Magenta Therapeutics

Aktien

A2JPD6

US55910K1088

MGTA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
21,5 ^USD	+2,43 %		-7,53 %	+92,07 %

2023	Dianthus Therapeutics, Inc. hat die Übernahme von Magenta Therapeutics, Inc. (NasdaqGM:MGTA) von einer Gruppe von Aktionären in einer Reverse-Merger-Transaktion abgeschlossen.	CI
2023	Magenta Therapeutics, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Adrenoleukodystrophy Clinical Trials, and Key Companies\|Companies - Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others	11.09.23
Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	11.09.23
Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	11.09.23
North American Morning Briefing : PCE Inflation -2-	31.08.23
North American Morning Briefing : Nasdaq Futures -2-	24.08.23
North American Morning Briefing : Treasury Yields Keep Pushing Higher	17.08.23
North American Morning Briefing : Attention Turns -2-	10.08.23
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	07.08.23
Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03.08.23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index	23.06.23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index	23.06.23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index	23.06.23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index	23.06.23
Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer	19.05.23
Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.05.23
North American Morning Briefing : Hopes Build for -3-	15.05.23
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	04.05.23
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	03.05.23
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement	03.05.23
Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction.	03.05.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Magenta Therapeutics

Aktien

A2JPD6

US55910K1088

MGTA

Andere Sprachen

Filter